Summary

This page summarises and signposts to publicly available information that we’re aware of from professional and government bodies relating to the Pfizer-BioNTech COVID-19 vaccine.

This page outlines the advice for patients with prophyria who are eligible for the COVID-19 vaccine.

More information

To see our professional guidance summaries for other clinical areas, click here

Areas of interest

Our summary of guidance grouped by themes for healthcare professionals.  Our advice is constantly reviewed as the pandemic situation evolves.

Advice for patients with porphyria

The UK Porphyria Medicines Information Service and the National Acute Porphyria Service consultants consider the new COVID-19 vaccines to be safe for use in those with acute porphyria.

They recommend those living with porphyria choose to receive the vaccination when it is offered.